These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 28770897)
21. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment. Petrović MJ; Sarenac T; Srećković S; Petrović M; Vulović D; Janićijević K Vojnosanit Pregl; 2012 Mar; 69(3):249-52. PubMed ID: 22624411 [TBL] [Abstract][Full Text] [Related]
22. Clinical features of Graves' ophthalmopathy in an incidence cohort. Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA Am J Ophthalmol; 1996 Mar; 121(3):284-90. PubMed ID: 8597271 [TBL] [Abstract][Full Text] [Related]
23. Graves' hyperthyroidism. Spontaneous occurrence after autoimmune hypothyroidism with persistent infiltrative ophthalmopathy. Sung LC; McDougall IR Arch Intern Med; 1978 Jun; 138(6):1009-10. PubMed ID: 580553 [TBL] [Abstract][Full Text] [Related]
24. Infiltrative ophthalmopathy and primary hypothyroidism: a rare clinical manifestation of a common disease. Rajput R; Dhingra A; Kumar K; Sen J Postgrad Med J; 2009 Jan; 85(999):40-2. PubMed ID: 19240288 [TBL] [Abstract][Full Text] [Related]
25. Exophthalmos and multinodular goitre, an unusual combination. Okolie K; Chen D; Ghabrial R; Schmidli R Endocrinol Diabetes Metab Case Rep; 2019 May; 2019():. PubMed ID: 31051471 [TBL] [Abstract][Full Text] [Related]
26. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves' ophthalmopathy. Jankauskiene J; Imbrasiene D Medicina (Kaunas); 2006; 42(11):900-3. PubMed ID: 17172791 [TBL] [Abstract][Full Text] [Related]
27. Response to tocilizumab treatment in Graves' ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography. de-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R Arch Soc Esp Oftalmol (Engl Ed); 2018 Aug; 93(8):386-391. PubMed ID: 29937157 [TBL] [Abstract][Full Text] [Related]
28. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy. Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160 [TBL] [Abstract][Full Text] [Related]
29. Diffusion-weighted magnetic resonance imaging of extraocular muscles in patients with Grave's ophthalmopathy using turbo field echo with diffusion-sensitized driven-equilibrium preparation. Hiwatashi A; Togao O; Yamashita K; Kikuchi K; Momosaka D; Honda H Diagn Interv Imaging; 2018; 99(7-8):457-463. PubMed ID: 29571699 [TBL] [Abstract][Full Text] [Related]
30. Orbital lymphoma associated with Graves' disease: A case report. Hajduković Z; Kuzmić-Janković S; Kljaković-Avramović T; Sekulović L; Tukić L Vojnosanit Pregl; 2014 May; 71(5):510-4. PubMed ID: 26137719 [TBL] [Abstract][Full Text] [Related]
31. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469 [TBL] [Abstract][Full Text] [Related]
32. A mild Grave's ophthalmopathy during pregnancy. Abbouda A; Trimboli P; Bruscolini A Semin Ophthalmol; 2014 Jan; 29(1):8-10. PubMed ID: 24171793 [TBL] [Abstract][Full Text] [Related]
33. Asymmetric Graves' Orbitopathy. Panagiotou G; Perros P Front Endocrinol (Lausanne); 2020; 11():611845. PubMed ID: 33391188 [TBL] [Abstract][Full Text] [Related]
34. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center. Leo M; Menconi F; Rocchi R; Latrofa F; Sisti E; Profilo MA; Mazzi B; Albano E; Nardi M; Vitti P; Marcocci C; Marinò M Thyroid; 2015 Mar; 25(3):347-51. PubMed ID: 25584927 [TBL] [Abstract][Full Text] [Related]
35. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases. Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466 [TBL] [Abstract][Full Text] [Related]
36. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Elbers L; Mourits M; Wiersinga W Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446 [TBL] [Abstract][Full Text] [Related]
37. Current insights of applying MRI in Graves' ophthalmopathy. Song C; Luo Y; Yu G; Chen H; Shen J Front Endocrinol (Lausanne); 2022; 13():991588. PubMed ID: 36267571 [TBL] [Abstract][Full Text] [Related]
38. Computed tomography and magnetic resonance imaging approaches to Graves' ophthalmopathy: a narrative review. Luccas R; Riguetto CM; Alves M; Zantut-Wittmann DE; Reis F Front Endocrinol (Lausanne); 2023; 14():1277961. PubMed ID: 38260158 [TBL] [Abstract][Full Text] [Related]
39. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children]. Chen DY; Chen TH Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551 [TBL] [Abstract][Full Text] [Related]
40. Severe Graves' ophthalmopathy may be a risk factor for the development of postthyroidectomy hypocalcaemia. Hassan I; Danila R; Maurer E; Osei-Agymang T; Zielke A Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):614-8. PubMed ID: 18523918 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]